Aarti Pharmalabs targets 40-50% CDMO growth as project pipeline shrinks
Management expects long-term revenue growth of 15-18% but faces near-term margin pressure from startup costs and raw material inflation.
— 3 earlier stories on Aarti Pharmalabs Ltd. →What's new
- Commercial-stage CDMO projects dropped to 35 from 40 in the previous quarter.
- Management targets 15-18% revenue and EBITDA CAGR over the next 3-4 years.
- A ₹400 crore capex plan is set for FY27, with intensity expected to drop from FY28.
Why this matters
The contraction in commercial-stage projects creates a tension with the aggressive 40-50% growth guidance. While management maintains a 20% EBITDA margin floor, the refusal to provide specific FY27 profit guidance suggests they expect the near-term margin compression to be persistent.
What we're watching
- Whether the project pipeline recovers in the coming quarters.
- The impact of West Asia-linked raw material inflation on margins.
- Actual capital expenditure execution against the ₹400 crore target.
The full read
Aarti Pharmalabs is betting on a 40-50% surge in its CDMO business for FY27, even as its commercial-stage project pipeline thins. The company reported a decline in active commercial projects to 35, down from 40 in the previous quarter. Management maintains a long-term revenue and EBITDA CAGR target of 15-18% over the next 3-4 years. To reach these goals, the firm has earmarked ₹400 crore for capex in FY27, with the expectation that spending intensity will ease from FY28 as current greenfield projects wrap up. Despite the growth targets, management refused to provide specific FY27 profit guidance. They remain committed to an EBITDA margin floor above 20%, though they acknowledge near-term pressure from startup costs and raw material inflation linked to the crisis in West Asia. The next test is whether the project pipeline can stabilize while the company absorbs these costs.
Questions answered
- What is the company's outlook for its CDMO business?
- Management expects the CDMO segment to grow by 40-50% in FY27. They also set a long-term target of 15-18% revenue and EBITDA CAGR over the next 3-4 years.
- How does the company plan to manage EBITDA margins?
- Management committed to keeping EBITDA margins above 20%. This is despite near-term headwinds from new facility startup costs and raw material inflation.
- What is the status of the company's project pipeline?
- The number of commercial-stage CDMO projects fell to 35, down from 40 in the prior quarter.
- What is the capital expenditure plan for FY27?
- The company plans to spend ₹400 crore on capex in FY27. They expect this intensity to decline from FY28 as the greenfield phase concludes.
Story so far
All notes on AARTIPHARM →- 26 May 2026 · 5:28 PM IST Aarti Pharmalabs targets 40-50% CDMO growth as project pipeline shrinks
- 1d ago Aarti Pharmalabs profit drops as finance costs and margins bite
- 2d ago Aarti Pharmalabs profit slides as costs and forex losses mount
- 2d ago Aarti Pharmalabs profit drops as derivative accounting error surfaces